All News SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Market Closed - Nasdaq Other stock markets 02:00:00 22/05/2024 am IST			5-day change	1st Jan Change
2.91 ^USD	-15.65%		-28.06%	-57.67%

20/05	SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics	21/05	AQ
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates	21/05	AQ
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	06/05	AQ
SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	06/05	CI
SAB Biotherapeutics Provides SAB-142 Trial Update	16/04	AQ
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	16/04	CI
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K	16/04	PU
SAB Biotherapeutics to Present at INNODIA Annual Meeting	08/04	AQ
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	04/04	AQ
HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating	02/04	MT
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	01/04	AQ
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K	29/03	PU
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	29/03	AQ
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	25/03	MT
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03	AQ
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03	CI
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference	26/02	AQ
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	23/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

All News

Filters